10-K: FONAR Reports FY2025 Net Income Decline Amidst Challenges

FONAR Corporation reported a decrease in net income for fiscal year 2025 to $10.7 million from $14.1 million in fiscal 2024, driven by higher operating costs and a significant credit loss reserve.

Summary

• Consolidated net income decreased to $10.7 million in fiscal year 2025 from $14.1 million in fiscal year 2024.
• Total revenues increased by 1.4% to $104.4 million in fiscal year 2025 from $102.9 million in fiscal year 2024.
• Consolidated operating income decreased by 29.7% to $11.6 million in fiscal year 2025 from $16.5 million in fiscal year 2024.
• Selling, general and administrative expenses increased by 10.7% to $29.7 million in fiscal year 2025, largely due to a $2.3 million increase in credit loss reserves for American Transit Insurance Company (ATIC).
• The physician and diagnostic services management segment (HMCA) revenues increased to $95.4 million in fiscal year 2025 from $94.6 million in fiscal year 2024, but its operating income decreased from $23.5 million to $19.2 million.
• Medical equipment segment revenues increased to $9.0 million in fiscal year 2025 from $8.4 million in fiscal year 2024, though product sales decreased by 23.6% to $563,000.
• The medical equipment segment's operating loss increased from $7.0 million in fiscal year 2024 to $7.6 million in fiscal year 2025.
• Cash and cash equivalents remained stable at $56.3 million at June 30, 2025 and 2024.
• Working capital increased to $127.5 million at June 30, 2025, from $122.5 million at June 30, 2024.
• A non-binding proposal was received on July 7, 2025, from a group led by the CEO and COO to acquire all outstanding common stock and other securities not currently owned by the group, potentially taking the company private.
• A material weakness in internal controls over information technology systems was identified for the fiscal year ending June 30, 2025.

Sentiment

Score: 4

Explanation: The company experienced a significant decline in net income and operating income, driven by increased expenses, particularly a large credit loss reserve, and decreased product sales. While revenues saw a slight increase and working capital improved, the identified material weakness in internal controls and ongoing challenges from reimbursement rates and competitive pressures indicate a cautious outlook. The non-binding going-private proposal adds uncertainty.

Positives

• Total revenues increased by 1.4% to $104.4 million in fiscal 2025.
• HMCA's physician and diagnostic services management segment revenues increased to $95.4 million in fiscal 2025.
• Service and repair fees increased by 10.8% to $8.4 million in fiscal 2025.
• Working capital increased to $127.5 million at June 30, 2025, from $122.5 million at June 30, 2024.
• Cash and cash equivalents remained stable at $56.3 million.
• Repaid outstanding debt for a Florida building during fiscal 2025, reducing interest expense.
• Formed Opus Diagnostic Management, LLC to service third-party MRI equipment, aiming for cost control and new revenue streams.
• Obtained four new patents in fiscal 2025, including one related to the development of a next-generation patient positioning system.
• The company has achieved profitability for the past five consecutive fiscal years (2021-2025).

Negatives

• Consolidated net income decreased to $10.7 million in fiscal 2025 from $14.1 million in fiscal 2024.
• Consolidated operating income decreased by 29.7% to $11.6 million in fiscal 2025.
• Total costs and expenses increased by 7.4% in fiscal 2025.
• Selling, general and administrative expenses increased by 10.7% to $29.7 million, primarily due to a $2.3 million increase in credit loss reserves for American Transit Insurance Company (ATIC), which is approaching insolvency.
• Medical equipment product sales decreased by 23.6% to $563,000 in fiscal 2025.
• The medical equipment segment's operating loss increased from $7.0 million in fiscal 2024 to $7.6 million in fiscal 2025.
• Patient fees (net of contractual allowances and discounts) from Florida facilities decreased by approximately $636,000 due to Florida's 2023 Tort Reform Act.
• A material weakness in internal controls over information technology systems was identified for the fiscal year ending June 30, 2025.
• Incurred unusual one-time expenses in fiscal 2025: $172,000 for New York City Commercial Rent Tax and $206,000 for unreported electricity bills.
• Research and development expenditures decreased by 9.2% in fiscal 2025.
• The company's common stock performance declined from $100 to $85 over the five years ending June 30, 2025, underperforming major market and industry indexes.

Risks

• Reduced reimbursement rates from Medicare, other government programs, and private insurance companies could negatively impact profitability.
• Inflation has drastically increased costs for materials and labor, making organic growth more difficult and threatening current operations' profitability.
• Cybersecurity threats, including data incidents, could materially disrupt operations, lead to significant costs, and potentially exceed insurance coverage; a material weakness in IT internal controls was identified.
• Dependence on patient referrals from unaffiliated physicians and third parties means a reduction in referrals would decrease scan volumes, net revenue, and operating margins.
• Current and future changes in Florida Insurance Law, particularly the 2023 Tort Reform Act, have negatively impacted Florida diagnostic imaging facilities, and a potential repeal of no-fault insurance could cause significant payment delays.
• The market for diagnostic imaging services is highly competitive, with many competitors possessing greater financial and other resources.
• Pressure to control healthcare costs from managed care organizations could lead to lower payment rates and reduced utilization of services.
• Eligibility changes to insurance programs, such as increased Medicaid participation or higher patient financial responsibility, could reduce reimbursement rates or increase uncollectible receivables.
• Reduced demand for MRI scanners due to lower reimbursement rates could lead to lower sales volumes and reduced profit margins.
• Manufacturing competition from larger companies (e.g., Siemens, GE, Philips) with greater resources could lead to heavy discounting of scanner prices.
• Adverse changes in general domestic and global economic conditions (tariffs, recessions, credit market disruptions, military conflicts) could negatively affect workforce, liquidity, financial condition, revenues, and profitability.
• The increasing use of radiology benefit managers (RBMs) could negatively impact the business by leading to lower utilization of imaging procedures.

Future Outlook

The company expects to complete the installation of an additional high field magnet in Lynbrook, NY, during fiscal year 2026 and plans to open a new diagnostic imaging facility in Nassau County, NY, before the end of fiscal year 2026. Capital resources are believed to be adequate to support operations through September 30, 2026. Opus Diagnostic Management, LLC is hoped to become a viable new revenue source and control maintenance costs. Novel research projects are anticipated to lead to new applications and upgrades. However, recent changes to Florida insurance laws are expected to result in lower no-fault auto insurance reimbursements and higher uncollectible billings, and New York Public Health Law Article 49A is also expected to negatively impact collection rates. The full impact of healthcare regulations and continuing changes in MRI scanning reimbursement rates cannot be accurately measured, and the company is evaluating the impact of the One Big Beautiful Act (OBBBA).

Management Comments

• We believe the utilization of FONAR Upright MRI scanning systems, which are produced under the protection of our patents, accounts for the historically robust patient volume at the scanning facilities.
• We believe that our efforts to expand and improve the operation of our physician and diagnostic services management segment are directly responsible for the profitability of this segment and our company as a whole.
• We hope these ventures [Opus Diagnostic Services, LLC and SwiftMRTM distribution] will develop into a viable source of new revenue in the future.
• We hope to control the cost of maintaining and repairing the outside manufacturer equipment operated by HMCA, and to expand into providing maintenance and repair services to other third party operators of outside manufacturer equipment.
• We hope to maintain service revenues at present levels, based on the demonstrated longevity of the Upright MRI scanner and continued customer satisfaction with the product.
• We believe that with time, that objective [convincing customers that FONAR scanner is best choice] will be reached, particularly with customers scanning patients having neck, back, knee and various orthopedic issues who would benefit from being scanned in weight-bearing positions.
• The Company believes that its business plan has been responsible for the past five consecutive fiscal years of profitability (fiscal 2025, fiscal 2024, fiscal 2023, fiscal 2022 and fiscal 2021), our current cash balance of $56.3 million, along with a working capital of $127.5 million and its capital resources will be adequate to support operations at current levels through September 30, 2026.

Industry Context

The healthcare industry is heavily regulated, with evolving laws and regulations impacting operational activities, costs, and reimbursement. The physician and diagnostic management services sector is highly competitive, marked by a trend of large health systems acquiring medical practices. The outpatient diagnostic imaging industry competes on physician referrals, managed care relationships, and specialized technology like the Upright MRI. Government and third-party payors are increasingly focused on cost containment, leading to lower reimbursement rates and stricter payment schedules. Commercial health insurance plans are shifting more financial responsibility to individuals, potentially delaying or reducing demand for medical procedures. The rising use of radiology benefit managers (RBMs) could further limit imaging procedure utilization. While MRI offers superior tissue contrast, it competes with other imaging modalities (x-ray, CT, nuclear medicine, ultrasound) on cost and space requirements.

Comparison to Industry Standards

• FONAR's Upright MRI operates at a mid-field strength of 0.6 T, while major competitors like Siemens, General Electric, Philips, Fujifilm, Canon, and United Imaging primarily focus on high-field (1.0 T and above) MRI.
• None of FONAR's major competitors have introduced an open, upright MRI, and other companies' success in this niche market has been limited, which FONAR believes gives it a competitive advantage due to its magnet's dimensions and patient positioning possibilities.
• The company's common stock performance declined from $100 to $85 over the five years ending June 30, 2025, underperforming the Nasdaq Composite (which grew to $145), Nasdaq Health Care Management Services (which grew to $91, but still outperformed FONR), and Nasdaq Medical Equipment (which grew to $104) indexes over the same period.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various litigation matters arising in the ordinary course of business, including personal injury, customer contract, and employment claims, but does not believe any current matter will have a material adverse effect.
• No material legal proceedings are threatened or pending against the Company.
• Uber has filed a lawsuit against American Transit Insurance Company (ATIC) alleging non-payment of claims.

Related Party Transactions

• Timothy Damadian, CEO and President, owns three HMCA-managed MRI facilities in Florida, which paid HMCA aggregate monthly management fees of $995,825 in fiscal 2025 and 2024.
• Magnetic Resonance Management, LLC, owned by Timothy Damadian, purchased an MRI scanner from the Company for $576,857, payable via a promissory note (balance $554,857 as of June 30, 2025).
• Bensonhurst MRI Limited Partnership, in which Timothy Damadian holds an interest, has two service and maintenance agreements with the Company for Upright MRI and High-Field Scanners, totaling $180,000 per annum.
• Bensonhurst MRI Limited Partnership was charged $301,480 in FY2025 and $190,362 in FY2024 for reimbursable salaries and marketing expenses.
• Radian Healthcare Management, LLC, owned by Matt Pluta (son-in-law of Timothy Damadian), provided personnel recruitment services for fees of $165,000 in FY2025 and $200,347 in FY2024.
• Ronald Lehman and Jessica Maher, Directors, hold interests in HMCA's Class A membership and receive distributions.
• Claudette J.V. Chan, former Director, held an interest in HMCA's Class A membership and received distributions.

Stakeholder Impact

• Shareholders: Potential impact from the proposed going-private transaction, which would de-list common stock from NASDAQ. Decreased net income and underperforming stock performance may concern investors. The stock repurchase program benefits shareholders.
• Employees: Required to receive cybersecurity training. Management changes affect board composition.
• Customers (Diagnostic Imaging Facilities): HMCA provides comprehensive management services, equipment, and support. These facilities are impacted by reduced reimbursement rates and changes in Florida insurance law.
• Patients: Benefit from Upright MRI technology for specific conditions and a non-claustrophobic experience. Patients are affected by changes in insurance coverage and the affordability of MRI scans.
• Creditors: Impacted by the company's financial health, particularly the credit loss reserve for American Transit Insurance Company (ATIC).
• Regulatory Authorities: The company is subject to federal and state healthcare regulations, including HIPAA, Stark Law, and Anti-Kickback Regulation, and must comply with FDA regulations for medical devices.

Next Steps

• Consider and negotiate the non-binding going-private proposal from a group led by the CEO and COO.
• Seek approval from common stockholders for any definitive agreement and transaction related to the going-private proposal.
• File definitive proxy materials in accordance with SEC proxy rules for the going-private transaction.
• Complete installation of an additional high field magnet in Lynbrook, NY, during fiscal year 2026.
• Open an additional diagnostic imaging facility in Nassau County, NY, before the end of fiscal year 2026.
• Continue efforts to remediate the material weakness in internal controls over information technology systems.
• Monitor the financial situation of American Transit Insurance Company (ATIC) for new developments and potential additional reserves.
• Monitor proposed changes to Florida insurance laws, including the potential repeal of no-fault insurance.
• Evaluate the impact of the One Big Beautiful Act (OBBBA) on financial condition and results of operations.
• Continue investing in research and development for Upright MRI upgrades and new applications.
• Expand Opus Diagnostic Management, LLC into providing maintenance and repair services to other third-party operators.

Key Dates

Recommendation

While FONAR maintains a strong cash position and working capital, and its HMCA segment shows revenue growth, the significant decline in net income and operating income in fiscal 2025 is concerning. This is primarily driven by a substantial credit loss reserve and increased operating costs. The identified material weakness in internal controls over IT systems adds a layer of operational risk. The non-binding going-private proposal introduces significant uncertainty but could offer a premium to current shareholders if completed. However, the underlying business challenges, including reduced reimbursement rates and intense competition, warrant a cautious approach. Investors should hold to monitor the outcome of the going-private transaction and the company's ability to address its operational and financial headwinds.

Keywords

MRI scanners, diagnostic imaging, healthcare management, SEC filing, FONAR, HMCA, Upright MRI, financial results, corporate governance, risk factors, medical equipment, physician management, NASDAQ, cybersecurity, reimbursement rates, inflation, related party transactions, going private proposal